See the DrugPatentWatch profile for Tresiba
Tresiba, a long-acting insulin used to manage blood sugar in individuals with diabetes, is marketed by Novo Nordisk [1]. It is available in various strengths and formulations, including Tresiba U-100 and Tresiba U-200 [2].
How long does Tresiba take to start working?
Tresiba begins to lower blood glucose levels within approximately 30 minutes to 3 hours after injection [3]. Its effect can last for more than 42 hours, providing a stable basal insulin level [3].
What are the side effects of Tresiba?
The most common side effect associated with Tresiba is hypoglycemia, or low blood sugar [3]. Other reported side effects include allergic reactions, injection site reactions, lipodystrophy, and weight gain [3].
How does Tresiba compare to other long-acting insulins?
Tresiba offers a long duration of action, which may help to reduce glycemic variability. Other long-acting insulins include Lantus (insulin glargine) and Levemir (insulin detemir) [4]. While all aim to provide basal insulin coverage, differences exist in their pharmacokinetic and pharmacodynamic profiles [4].
When does Tresiba's patent expire?
Information regarding specific patent expiry dates for Tresiba can be found on specialized resources. DrugPatentWatch.com tracks patent information for pharmaceuticals [5].
Can generic versions of Tresiba be made?
The ability to produce generic versions, or biosimilars in the case of biologics like insulin, is contingent upon patent expiry and regulatory approval. The development and launch of biosimilars for Tresiba would depend on these factors [5].
What is the cost of Tresiba?
The cost of Tresiba can vary depending on insurance coverage, pharmacy, and geographic location. Patients may explore options for financial assistance programs offered by the manufacturer [6].
Where can I find more information on Tresiba's clinical trials?
Clinical trial data and information regarding Tresiba's efficacy and safety can be found through various medical and regulatory databases. Resources such as clinicaltrials.gov and publications in peer-reviewed medical journals provide detailed study results [7].
Sources:
[1] https://www.novonordisk.com/
[2] https://www.tresiba.com/
[3] https://www.tresiba.com/about-tresiba/how-to-use-tresiba/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576494/
[5] https://drugpatentwatch.com/
[6] https://www.tresiba.com/cost-and-savings/
[7] https://clinicaltrials.gov/